Background: The aim of this study was to assess the diagnostic performance of an autoantibody battery in patients receiving immune checkpoint inhibitors who experienced immune-related adverse events (irAEs).
Methods: We retrospectively analyzed several variables potentially related to irAEs, namely, demographic, clinical, and laboratory characteristics, including an autoantibody battery (antinuclear, anti-neutrophil cytoplasmic, anti-thyroid antibodies and rheumatoid factor).
Results: Sixty-nine patients (48 men; 61.8 ± 10.9 years at baseline) diagnosed with stage-4 solid-organ cancer and treated with nivolumab were followed up for 12 ± 10.3 months. Thirty-two irAEs were detected in 26 patients (37.5%). Adverse events occurred more commonly in women (62% vs. 27%, = .006), and younger patients (irAEs: 58.1 ± 9.8, no irAEs: 64.1 ± 10.9 years, = .024). Autoantibody battery results were available for 26 patients and were more frequently positive in patients with irAEs (87% vs. 30%, = .009). The positive predictive value, negative predictive value, and diagnostic accuracy of the battery were 82.3%, 77.8%, and 80.8%, respectively. Among the 64 patients with an evaluable response, 23 (38.5%) experienced tumour progression, this being less frequent in patients with irAEs (19% vs. 48.5%, = .03). Overall survival was higher in patients developing irAEs (HR = 1.88, = .05).
Conclusion: Positivity in a readily available autoantibody battery may be associated with the occurrence of irAEs.KEY MESSAGESPositivity in an accessible and inexpensive autoantibody battery including antinuclear, anti-neutrophil cytoplasmic, anti-thyroid antibodies and rheumatoid factor may be associated with the occurrence of immune-related adverse events.Patients with cancer on immune checkpoint inhibitors experiencing immune-related adverse events showed a lower risk of progression and better overall survival than patients not experiencing this type of adverse effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172225 | PMC |
| http://dx.doi.org/10.1080/07853890.2021.1931956 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum anti-NMDA receptor antibodies are linked to memory impairment 12 months after stroke.
Mol Psychiatry
October 2024
Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.
Article Synopsis
- Patients who have suffered a stroke are at higher risk for developing post-stroke dementia, and the presence of serum anti-NMDA receptor autoantibodies (NMDAR1-abs) may negatively impact cognitive outcomes, particularly memory.
- In a study using the DEMDAS cohort, researchers found that 10.2% of stroke patients were seropositive for NMDAR1-abs, but this did not correlate with overall cognitive decline.
- However, those with NMDAR1-abs did show significantly worse performance in memory tasks and were more likely to experience memory impairment one year post-stroke, indicating a specific link between these autoantibodies and memory dysfunction.
Outcome clusters and their stability over 1 year in patients with SLE: self-reported and performance-based cognitive function, disease activity, mood and health-related quality of life.
Lupus Sci Med
July 2024
Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada
Article Synopsis
- The study aims to identify distinct groups based on symptom intensity (fatigue, anxiety, depression, etc.) in patients with Systemic Lupus Erythematosus (SLE) and observe changes over a year.
- Results showed three symptom intensity clusters: mild, moderate, and severe, with varying stability; 49% of patients remained in their initial cluster after one year, particularly those in the mild cluster (77%).
- The findings suggest that patients in moderate symptom clusters could benefit from interventions to better manage their symptoms and potentially prevent deterioration to severe levels.
Remote digital cognitive assessment reveals cognitive deficits related to hippocampal atrophy in autoimmune limbic encephalitis: a cross-sectional validation study.
EClinicalMedicine
March 2024
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.
Background: Autoimmune limbic encephalitis (ALE) is a neurological disease characterised by inflammation of the limbic regions of the brain, mediated by pathogenic autoantibodies. Because cognitive deficits persist following acute treatment of ALE, the accurate assessment of long-term cognitive outcomes is important for clinical assessments and trials. However, evaluating cognition is costly and an unmet need exists for validated digital methods.
View Article and Find Full Text PDFA Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1-42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model.
J Alzheimers Dis
March 2024
Department of Geriatrics and Gerontology, New Jersey Institute for Successful Aging, Rowan-Virtua School of Osteopathic Medicine, Rowan University, Stratford, NJ, USA.
Background: Increased blood-brain barrier (BBB) permeability and amyloid-β (Aβ) peptides (especially Aβ1-42) (Aβ42) have been linked to Alzheimer's disease (AD) pathogenesis, but the nature of their involvement in AD-related neuropathological changes leading to cognitive changes remains poorly understood.
Objective: To test the hypothesis that chronic extravasation of bloodborne Aβ42 peptide and brain-reactive autoantibodies and their entry into the brain parenchyma via a permeable BBB contribute to AD-related pathological changes and cognitive changes in a mouse model.
Methods: The BBB was rendered chronically permeable through repeated injections of Pertussis toxin (PT), and soluble monomeric, fluorescein isothiocyanate (FITC)-labeled or unlabeled Aβ42 was injected into the tail-vein of 10-month-old male CD1 mice at designated intervals spanning ∼3 months.
IgLON5 deficiency produces behavioral alterations in a knockout mouse model.
Front Immunol
February 2024
Neuroimmunology Program, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomédiques August Pi i Sunyer-Caixa Research Institute (CRI), Universitat de Barcelona, Barcelona, Spain.
Article Synopsis
- Anti-IgLON5 disease is a neurological disorder linked to autoantibodies against IgLON5, affecting brain health and behavior, but the exact function of IgLON5 is still unknown.!
- Researchers created IgLON5 knockout (KO) mice using CRISPR-Cas9 to study changes in brain morphology and behavior, conducting tests on locomotion, memory, anxiety, social interaction, and depressive-like behaviors.!
- Although IgLON5-KO mice displayed minor behavioral changes and motor coordination issues, they did not show the severe symptoms or brain changes typical of anti-IgLON5 disease seen in humans, suggesting different mechanisms at play.!
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!